Advanced search
Publication Cover
Pharmacogenomics Volume 15, 2014 - Issue 2
Submit an article Journal homepage
477
Views
0
CrossRef citations to date
0
Altmetric
Research Article

CYP3A5 and CYP3A4, but not ABCB1 Polymorphisms Affect Tacrolimus Dose-Adjusted Trough Concentrations in Kidney Transplant Recipients

Mateusz Kurzawski1 Department of Experimental & Clinical Pharmacology, Pomeranian Medical University, Powstancow Wielkopolskich, 72, 70–111Szczecin, PolandCorrespondence[email protected]
,
Justyna Dąbrowska1 Department of Experimental & Clinical Pharmacology, Pomeranian Medical University, Powstancow Wielkopolskich, 72, 70–111Szczecin, Poland
,
Krzysztof Dziewanowski2 Clinical Department of Nephrology & Dialysis, Marie Curie Regional Hospital, Arkonska 4, 71–455Szczecin, Poland
,
Leszek Domański3 Department of Nephrology, Transplantation & Internal Medicine, Pomeranian Medical University, Powstancow Wielkopolskich 72, 70–111Szczecin, Poland
,
Magdalena Perużyńska1 Department of Experimental & Clinical Pharmacology, Pomeranian Medical University, Powstancow Wielkopolskich, 72, 70–111Szczecin, Poland
&
Marek Droździk1 Department of Experimental & Clinical Pharmacology, Pomeranian Medical University, Powstancow Wielkopolskich, 72, 70–111Szczecin, Poland
Pages 179-188 | Received 21 Aug 2013, Accepted 30 Sep 2013, Published online: 21 Jan 2014

References

  • Lee RA , GabardiS. Current trends in immunosuppressive therapies for renal transplant recipients. Am. J. Health Syst. Pharm.69(22) , 1961–1975 (2012).
  • Wallemacq P , ArmstrongVW, BrunetM et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31(2) , 139–152 (2009).
  • Shiraga T , MatsudaH, NagaseK et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol. 47(4) , 727–735 (1994).
  • Terrazzino S , QuagliaM, StrattaP, CanonicoPL, GenazzaniAA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet. Genomics22(8) , 642–645 (2012).
  • Adler G , LoniewskaB, ParczewskiM, KordekA, CiechanowiczA. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol. Rep.61(5) , 947–951 (2009).
  • Hashimoto H , ToideK, KitamuraR et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218(2) , 585–595 (1993).
  • Birdwell KA , GradyB, ChoiL et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22(1) , 32–42 (2012).
  • Elens L , van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors‘ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics12(10) , 1383–1396 (2011).
  • Wang D , GuoY, WrightonSA, CookeGE, SadeeW. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4) , 274–286 (2011).
  • Saeki T , UedaK, TanigawaraY, HoriR, KomanoT. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem.268(9) , 6077–6080 (1993).
  • Li Y , HuX, CaiB et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transplant. Immunol. 27(1) , 12–18 (2012).
  • Hoffmeyer S , BurkO, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA97(7) , 3473–3478 (2000).
  • Kimchi-Sarfaty C , OhJM, KimIW et al. A ‘silent‘ polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811) , 525–528 (2007).
  • Balbontin FG , KiberdB, SquiresJ et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transplant. Proc. 35(7) , 2445–2448 (2003).
  • Scholten EM , CremersSC, SchoemakerRC et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 67(6) , 2440–2447 (2005).
  • Rebbeck TR , TroxelAB, WangY et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst. 98(18) , 1311–1320 (2006).
  • Elens L , BouamarR, HesselinkDA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11) , 1574–1583 (2011).
  • Kurzawski M , DrozdzikM. Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs. Pharmacogenomics14(9) , 1099–1118 (2013).
  • Klein K , ZangerUM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the ‘missing heritability‘ problem. Front. Genet.4 , 12 (2013).
  • Rebbeck TR , JaffeJM, WalkerAH, WeinAJ, MalkowiczSB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst.90(16) , 1225–1229 (1998).
  • Amirimani B , NingB, DeitzAC, WeberBL, KadlubarFF, RebbeckTR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen.42(4) , 299–305 (2003).
  • Hesselink DA , van Schaik RHN, van der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74(3) , 245–254 (2003).
  • Tavira B , CotoE, Diaz-CorteC, AlvarezV, Lopez-LarreaC, OrtegaF. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenet. Genomics23(8) , 445–448 (2013).
  • Gervasini G , GarciaM, MaciasRM, CuberoJJ, CaravacaF, BenitezJ. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transplant. Int.25(4) , 471–480 (2012).
  • Roy JN , BaramaA, PoirierC, VinetB, RogerM. CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics16(9) , 659–665 (2006).
  • Santoro AB , StruchinerCJ, FelipeCR, Tedesco-SilvaH, Medina-PestanaJO, Suarez-KurtzG. CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin. Pharmacol. Ther.94(2) , 201–202 (2013).
  • Gijsen VM , van Schaik RH, Elens L et al.CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics14(9) , 1027–1036 (2013).
  • Sadee W , WangD, PappAC et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin. Pharmacol. Ther. 89(3) , 355–365 (2011).
  • Klein K , ThomasM, WinterS et al. PPARA: a novel genetic determinant of CYP3A4in vitro and in vivo. Clin. Pharmacol. Ther. 91(6) , 1044–1052 (2012).
  • Kuypers DR , NaesensM, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit.32(4) , 394–404 (2010).
  • Tavira B , GarciaEC, Diaz-CorteC et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49(5) , 825–833 (2011).
  • Haufroid V , MouradM, Van Kerckhove V et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics14(3) , 147–154 (2004).
  • Thervet E , LoriotMA, BarbierS et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6) , 721–726 (2010).
  • Passey C , BirnbaumAK, BrundageRC, OettingWS, IsraniAK, JacobsonPA. Dosing equation for tacrolimus using genetic variants and clinical factors. Br. J. Clin. Pharmacol.72(6) , 948–957 (2011).
  • Passey C , BirnbaumAK, BrundageRC et al. Validation of tacrolimus equation to predict troughs using genetic and clinical factors. Pharmacogenomics 13(10) , 1141–1147 (2012).
  • Boughton O , BorgulyaG, CecconiM, FredericksS, Moreton-ClackM, MacPheeIA. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br. J. Clin. Pharmacol.76(3) , 425–431 (2013).
  • Elens L , HesselinkDA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br. J. Clin. Pharmacol.75(6) , 1545–1547 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.